Program notes:

0:38 Childhood vaccinations nationally

1:30 Across 45 states and DC

2:34 Level of vaccine protection

3:34 Professional societies stepping in

3:51 Skilled nursing facilities 

4:51 Estimated operating capacity

5:51 Backups into hospitals

6:51 Staffing not returned to pre-pandemic levels

7:35 Prescribing patterns of CNS active meds in older adults

8:36 Several classes of medication examined

9:36 Last line medications

9:50 Mifepristone regulation historically

10:50 Consistent findings on safety

11:50 FDA looking at REMS

12:50 End

Program notes:

0:35 Global pain burden

1:35 Prevalence increased in 15 countries

2:35 Higher prevalence in older people but not consequence of aging

3:02 Tertiary patents

4:03 in the Orange Book

5:05 Prolonged patent protection and higher prices

6:07 Focused on high revenue products

6:50 Detecting DVT better

7:51 Age specific D-dimer cutoffs

8:51 Age and morbidity factors

9:23 Infant screen time and adolescent anxiety

10:24 Multiple intermediate assessments

11:24 Accelerates development

12:47 End

Program notes:

0:40 IVF clinics and private equity

1:40 Provide over 54% of all IVF cycles in U.S.

2:41 Perhaps a more positive result

3:30 EKGs and liver cirrhosis

4:30 New diagnosis of advanced liver disease

5:30 Most physicians didn't follow up

6:18 Management of acute back pain

7:18 Did it improve pain or disability?

8:18 Four- to eight-hour-long sessions to teach

8:46 Lay health worker led intervention for older adults with cancer

9:46 Reviewed with advanced practice practitioners

10:46 Huge benefit from modest intervention

11:46 Pick up the phone and ask

12:20 Modest outlay

13:09 End

Program notes:

0:40 Saturated fat and CVD

1:40 When it was reduced in diet only helped in those with high risk

2:40 Obesity, diabetes and metabolic syndrome also important

3:30 Diagnostic follow up after lung CT

4:30 Less intensive than recommended in non-Hispanic blacks

5:31 Herpes antiviral and Alzheimer's

6:30 Followed for five years

7:30 80-90% of population exposed

8:30 Change screening criteria for lung ca

9:33 Population based study

10:30 Calculating pack years

11:20 Rolling out through national organizations

12:17 End

Program notes:

0:37 Breast density knowledge outcomes

1:37 Breast density notification and education

2:37 Can't assess the import individually

3:30 CV outcomes with tirzepatide

4:30 HbA1c 8.4

5:30 GLP-1s have many benefits

6:30 No difference in adverse events

7:10 Covid vaccination in pregnancy

8:10 20K women included

9:10 Initial benefit is it durable?

9:30 Complex regional pain syndrome treatment

10:30 Using bisphosphonates for treatment

11:33 Even light contact causes severe pain

12:28 End

Program notes:

0:35 Should surgery efficacy

1:30 10-year follow of ASD surgery

2:30 Exercise does relieve pain

3:00 Association of pain with intrinsic capacity and inflammation

4:00 Domains including locomotion and others

5:01 Pain impacts a number of capacities

6:01 Aspirational to figure out pain

6:30 Scheduling birth at term to avoid preeclampsia

7:30 High-risk pregnancy delivered at term

8:35 Is there impact on the infants?

9:18 AI decision support for large-vessel stroke

10:20 71,000+ patients with ischemic stroke

11:25 U.S. data also not impressive

12:54 End

Program notes:

0:35 Update on RSV, flu and COVID-19 vaccines

1:35 500 studies included

2:35 Rare myocarditis

3:35 Flu vaccine in older adults

4:30 Tai chi or CBT-I for chronic insomnia

5:30 Trained in one or the other

6:30 Inexpensive and accessible

7:30 $150 billion cost of chronic insomnia

7:45 GLP-1s and WHO guidance

8:50 Multimodal approach required

9:45 Prevention is important

9:55 Corticosteroids in pregnancy

10:50 1.3 million pregnancies

11:50 Used for multiple indications

12:46 End

Program notes:

0:40 CVD risk factors and texting

1:40 How many undergo screening?

2:41 Impact of personalized messaging

3:25 Decentralized trials versus centralized 

4:25 Decentralized much larger

5:25 Does the trial move in one way or another?

6:15 Two studies related to use of peripregnancy GLP-1 use

7:15 Stopping at pregnancy

8:15 Is overweight worse than stopping?

9:00 Machine learning model, tissues, genetics and age

10:00 Practical for assessing genetic basis

11:00 Sequential tissue samples

11:57 End

Program notes:

1:25 mRNA flu vaccine

2:25 Phase three trial

3:25 Preventing infection with a respiratory virus

4:25 Prophylaxis with NSAID?

4:45 Umbrella review of acetaminophen in pregnancy, ASD and ADHD

5:42 Confidence was low to critically low

6:45 Other factors such as environmental exposures

7:22 Increasing potassium to prevent heart arrythmias

8:33 Increase with supplements or dietary advice

9:18 Canceling funding for clinical trials

10:18 In the process of receiving interventions

11:18 Can't not analyze 

12:15 End

Program notes:

0:50 Fish oil supplements and hemodialysis

1:50 1200 individuals to fish oil or not

2:50 Needs another study

3:11 PCSK9 inhibitor in people without MI or stroke

4:13 3- or 4-point MACE

5:11 Getting LDL down helps

6:11 Addition of more than one oral agent

6:50 Right therapy for afib and a stent

7:50 Noninferiority trial

8:50 After 12 months single agent works

9:27 Anticoagulation after afib tx

10:30 Low primary safety outcomes

11:25 96% won't have a stroke

12:16 End